You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

Article info

Article menu
Immunotherapy biomarkers
Original research
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

Authors

  • Grace Heloise Attrill Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Carina N Owen Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaThe University of Bristol, Bristol Cancer Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK PubMed articlesGoogle scholar articles
  • Tasnia Ahmed Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Ismael A Vergara Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Andrew J Colebatch Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaDepartment of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Jordan W Conway Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Kazi J Nahar Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • John F Thompson Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaDepartment of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital; Mater Hospital, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Ines Pires da Silva Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaWestmead and Blacktown Hospitals, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Matteo S Carlino Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaWestmead and Blacktown Hospitals, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Alexander M Menzies Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaRoyal North Shore and Mater Hospitals, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Serigne Lo Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Umaimainthan Palendira Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Richard A Scolyer Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaDepartment of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Georgina V Long Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaRoyal North Shore and Mater Hospitals, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • James S Wilmott Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr James S Wilmott; james.wilmott{at}sydney.edu.au
View Full Text

Citation

Attrill GH, Owen CN, Ahmed T, et al
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
Journal for ImmunoTherapy of Cancer 2022;10:e004771. doi: 10.1136/jitc-2022-004771

Publication history

  • Accepted May 4, 2022
  • First published June 10, 2022.
Online issue publication 
January 24, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.